Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Next Previous
Trial Profile

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Leronlimab (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CytoDyn

Most Recent Events

  • 01 Jul 2025 According to CytoDyn media release, data from a retrospective analysis of this study along with NCT04313075 and NCT04504942, was presented at the 2025 ESMO Breast Cancer meeting.
  • 07 Jun 2022 Results of pooled analysis from NCT03838367, NCT04313075, NCT04504942; exploring the effect of leronlimab on circulating tumor associated cells (TACs) from peripheral blood as a surrogate and early predictor of drug response, presented at the 58th Annual Meeting of the American Society of Clinical Oncolog
  • 13 Apr 2022 Blood sample from 3 studies (NCT03838367, NCT04313075 & NCT04504942) were used to assess the predictive value of TACs, measured by the LifeTracDx assay, presented at the 113th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top